Baxter International (BAX) Given Media Sentiment Score of 0.14

Media stories about Baxter International (NYSE:BAX) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Baxter International earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.3767788494606 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Several research analysts have weighed in on BAX shares. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a research report on Tuesday, October 24th. BMO Capital Markets reissued a “buy” rating and issued a $70.00 price objective on shares of Baxter International in a research note on Friday, October 13th. Bank of America raised shares of Baxter International from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 2nd. Morgan Stanley increased their price objective on shares of Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 26th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $60.00 price objective on shares of Baxter International in a research note on Tuesday, October 3rd. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $68.64.

Baxter International (BAX) traded down $0.12 during mid-day trading on Friday, reaching $68.34. 2,370,000 shares of the company’s stock traded hands, compared to its average volume of 2,820,000. Baxter International has a fifty-two week low of $45.47 and a fifty-two week high of $69.65. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $37,230.00, a price-to-earnings ratio of 36.94, a P/E/G ratio of 2.08 and a beta of 0.69.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.05. The firm had revenue of $2.71 billion during the quarter, compared to analyst estimates of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business earned $0.56 EPS. research analysts anticipate that Baxter International will post 2.43 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st were issued a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.94%. Baxter International’s dividend payout ratio (DPR) is presently 34.59%.

In other news, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeanne K. Mason sold 33,350 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the completion of the sale, the senior vice president now owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. Insiders sold a total of 5,061,991 shares of company stock valued at $325,245,035 in the last 90 days. Company insiders own 0.05% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Baxter International (BAX) Given Media Sentiment Score of 0.14” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with's FREE daily email newsletter.

Leave a Reply